Pneumonia Treatment Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 8.20 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Pneumonia Treatment Market Analysis
The pneumonia treatment market is expected to register a CAGR of 8.2% during the forecast period.
The COVID-19 pandemic has had an impact on the pneumonia treatment market as patients suffering from COVID-19 are highly susceptible to pneumonia, causing a sharp surge in the number of cases of viral pneumonia. As per the NIH updated in September 2022, Hospitalized patients with COVID-19 may acquire common nosocomial infections, such as hospital-acquired pneumonia (including ventilator-associated pneumonia). Moreover, as per the study published in July 2021 by the British medical journal, The COVID-19 pandemic led to an unprecedented surge in hospitalized patients with viral pneumonia. Early diagnosis and treatment of these infections are important for improving outcomes in these patients. Thus, COVID-19 impacted the pneumonia treatment market, owing to the growth in demand for COVID-19-associated pneumonia and the surge in the incidence of pneumonia cases during the commenced period. However, even after the pandemic, the market is expected to see a surge due to an increase in lung injuries in many people with COVID-19. For instance, as per the study published In March 2022, By the Radiological Society of North America, Long-term CT abnormalities were common 1 year after COVID-19 pneumonia.
The major contributing factors to the market growth are the increasing prevalence of pneumonia and increasing product approvals related to the treatment of pneumonia. For instance, as per the UNICEF data updated in August 2021, globally, there are over 1,400 cases of pneumonia per 100,000 children, or 1 case per 71 children every year, with the greatest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children). Thus, with the increasing cases of pneumonia, the demand for its treatment is also expected to increase, which is further expected to boost the growth of the market over the forecast period.
Moreover, an increasing number of ongoing clinical trials for the development of drug molecules and various approvals by the key players will have a significant impact on the market progression. Currently, different companies operating in the pneumonia therapeutics market, including Merck and GSK, are putting enormous efforts into research and development activities. For instance, in February 2020, Food and Drug Administration accepted the review supplemental new drug application for Recarbrio for the treatment of adults with ventilator-associated and hospital-acquired bacterial pneumonia. In June 2021, the US FDA approved PREVNAR 20, Pfizer's pneumococcal 20-valent conjugate vaccine for adults ages 18 years or older, for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumonia (pneumococcus) serotypes in the vaccine. Thus, such developments are expected to boost the growth of the pneumonia treatment market over the forecast period.
However, low treatment rates in developing economies are expected to hinder the growth of the market over the forecast period.
Pneumonia Treatment Market Trends
This section covers the major market trends shaping the Pneumonia Treatment Market according to our research experts:
Aminopenicillin Segment is Expected to Exibhit a Steady Growth in the Pneumonia Treatment Market
Aminopenicillin is a group of antibiotics that are usually used for the treatment of upper and lower respiratory tract infections. Amoxicillin, a penicillin-like drug, is the first-line treatment of community-acquired pneumonia infection, according to the Infectious Disease Society of America. Amoxicillin binds to penicillin-binding proteins that activate an autolytic enzyme that destroys the bacterial cell wall and thereby kills the bacterial cell.
As per the study published by the National Library of Medicine, in June 2021, over the study period, a favorable trend was seen as aminopenicillin prescriptions (20.1% to 31.8%) increased and prescriptions for macrolides decreased (45.8% to 40.5%). Thus, the adoption of aminopenicillin for the treatment of pneumonia over the other drugs is expected to boost the growth of the segment over the forecast period.
Furthermore, the number of hospital stays is higher in the case of adults, which makes them at a greater risk of hospital-acquired pneumonia. For instance, as per the study published in September 2021 by Med Care, 1.2% of hospitalizations were 21 days or longer. Patients with prolonged hospitalizations were younger and had a greater number of chronic diseases. Thus, the increasing number of hospital stays is expected to increase in the cases of hospital-acquired pneumonia, which is expected to boost the growth of the market over the forecast period.
Thereby, the growing burden of pneumonia, advantages associated with aminopenicillins, and the high number of hospital stays are expected to drive the market in this segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global pneumonia treatment market due to the growing burden of pneumonia infection and increasing product approvals. For instance, as per the study published in August 2021 by NCBI, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases. Thus, such an increased burden of community-acquired pneumonia in the country is expected to increase the demand for its treatment which is expected to influence positively on the pneumonia treatment market.
Also, the increasing launches by manufacturers to meet the growing demand for innovative products are expected to drive market growth. For instance, in June 2021, The US FDA approved omadacycline, an oral-only dosing regimen, for the treatment of community-acquired bacterial pneumonia. Such factors potentially drive the demand for the adoption of pneumonia treatment in the region.
Thus, all the aforementioned factors are expected to boost the market in the region over the forecast period.
Pneumonia Treatment Industry Overview
The Pneumonia Treatment Market is fragmented and consists of several major players. Some of the companies which are currently dominating the market are Pfizer Inc., Teva Pharmaceuticals Inc., Abbott, Baxter International, and Viatris.
Pneumonia Treatment Market Leaders
-
Pfizer Inc.
-
Teva Pharmaceuticals Inc.
-
Abbott
-
Baxter International
-
Viatris
*Disclaimer: Major Players sorted in no particular order
Pneumonia Treatment Market News
- September 2022: Merck announced that the CHMP approved VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) (pronounced VAKS-noo-vans) for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.
- September 2022: Pfizer announced positive top-line results from its pivotal European Union Phase III study in infants (NCT04546425) evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD), pneumonia, and acute otitis media caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
Pneumonia Treatment Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Burden of Pneumonia
- 4.2.2 Rising Number of Ongoing Clinical Trials for Vaccine Development and Drug Molecules
-
4.3 Market Restraints
- 4.3.1 Low Treatment Rates in Developing Economies
-
4.4 Porter Five Forces
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Drug Type
- 5.1.1 Quinolone
- 5.1.2 Macrolide
- 5.1.3 Aminopenicilin
- 5.1.4 Cephalosporins
- 5.1.5 Glycopeptide Antibiotics
- 5.1.6 Others
-
5.2 By Distribution Channel
- 5.2.1 Hospital Pharmacies
- 5.2.2 Retail Pharmacies
- 5.2.3 Others
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle-East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle-East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott
- 6.1.2 AbbVie
- 6.1.3 Akorn Inc.
- 6.1.4 Baxter International Inc.
- 6.1.5 Lupin Pharmaceuticals Inc.
- 6.1.6 Viatris
- 6.1.7 Neopharma
- 6.1.8 Novartis AG
- 6.1.9 Pfizer Inc.
- 6.1.10 Teva Pharmaceuticals Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityPneumonia Treatment Industry Segmentation
As per the scope of the report, pneumonia is an acute respiratory disease in which pus and fluid are filled in the small sacs and alveoli of the lung, which makes breathing difficult. It is generally caused by Streptococcus Pneumoniae, Haemophilus influenzae, Pneumocystis jiroveci, and HIV infections. The pneumonia treatment market is segmented By Drug Type (Quinolone, Macrolide, Aminopenicillin, Cephalosporins, Glycopeptide Antibiotics, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others). The report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Drug Type | Quinolone | |
| Macrolide | ||
| Aminopenicilin | ||
| Cephalosporins | ||
| Glycopeptide Antibiotics | ||
| Others | ||
| By Distribution Channel | Hospital Pharmacies | |
| Retail Pharmacies | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle-East and Africa | GCC |
| South Africa | ||
| Rest of Middle-East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Pneumonia Treatment Market Research FAQs
What is the current Pneumonia Treatment Market size?
The Pneumonia Treatment Market is projected to register a CAGR of 8.20% during the forecast period (2024-2029)
Who are the key players in Pneumonia Treatment Market?
Pfizer Inc., Teva Pharmaceuticals Inc., Abbott, Baxter International and Viatris are the major companies operating in the Pneumonia Treatment Market.
Which is the fastest growing region in Pneumonia Treatment Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Pneumonia Treatment Market?
In 2024, the North America accounts for the largest market share in Pneumonia Treatment Market.
What years does this Pneumonia Treatment Market cover?
The report covers the Pneumonia Treatment Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Pneumonia Treatment Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Pneumonia Treatment Industry Report
Statistics for the 2024 Pneumonia Treatment market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pneumonia Treatment analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
